The hsa_circ_0082152 maintains NF-κB mRNA stability by binding to MTDH to promote anti-tuberculosis drug-induced

Lin Wang1, Chunyan Meng1, Yifei Long1

  • 1Hebei Coordinated Innovation Center of Occupational Health and Safety, School of Public Health, North China University of Science and Technology, Tangshan, Hebei Province, China.

Insights

Anti-tuberculosis drug-induced liver injury (ADLI) involves inflammation. Circular RNA hsa_circ_0082152 promotes ADLI by stabilizing NF-κB mRNA through interaction with MTDH, increasing inflammatory factors.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Immunology

Background:

  • Anti-tuberculosis drug-induced liver injury (ADLI) is a frequent complication of tuberculosis treatment, often necessitating treatment cessation.
  • Circular RNAs (circRNAs) are implicated as critical regulators in the pathogenesis of liver diseases, including inflammatory processes.

Purpose of the Study:

  • To investigate the role of circular RNA hsa_circ_0082152 in the development of ADLI.
  • To elucidate the molecular mechanism by which hsa_circ_0082152 influences ADLI progression.

Main Methods:

  • Serum analysis of ADLI patients revealed elevated hsa_circ_0082152 levels correlating with liver injury markers and inflammatory factors.
  • An in vitro HL-7702-ADLI cell model was established to confirm the upregulation of hsa_circ_0082152.
  • RNA immunoprecipitation assays were employed to identify interacting proteins, specifically metadherin (MTDH).

Main Results:

  • Downregulation of hsa_circ_0082152 mitigated inflammatory injury in the ADLI cell model, while its overexpression exacerbated it.
  • hsa_circ_0082152 was found to interact with MTDH, a protein that binds to NF-κB mRNA.
  • This interaction stabilizes NF-κB mRNA, leading to increased expression of NF-κB and its downstream inflammatory targets (IL-1β, TNF-α).

Conclusions:

  • hsa_circ_0082152 promotes ADLI progression through the MTDH/NF-κB signaling pathway.
  • Targeting hsa_circ_0082152 or the MTDH/NF-κB axis may offer a therapeutic strategy for managing ADLI.